Patents by Inventor Glen D. Leesman
Glen D. Leesman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6996473Abstract: A secondary compound library produced by a method of screening a compound library or portion thereof by absorption is provided. The method includes a step (i) that screens a primary compound library or portion thereof having a plurality of test samples containing isolated compounds or isolated mixtures of compounds per test sample by generating an in vivo absorption profile for each of the test samples from initial dose data and from in vitro bioavailability data comprising permeability and solubility data for each of the test samples, wherein the absorption profile includes at least one of rate of absorption, extent of absorption, and concentration of a test sample. Step (ii) produces a secondary compound library that includes at least one compound from the primary compound library having a desired absorption profile.Type: GrantFiled: November 21, 2001Date of Patent: February 7, 2006Assignee: Lion Bioscience AGInventors: George M. Grass, Glen D. Leesman, Daniel A. Norris, Patrick J. Sinko, John E. Wehrli
-
Publication number: 20040180322Abstract: Permeability models and methods for creating the models are disclosed. The models include receiving as an input in vitro permeability and structure data for a particular compound. Then the data is mapped to at least one permeability. In some models the data is mapped to a plurality of permeabilities, each associated with a specific region in a mammalian GI tract. Some models may take into consideration solubility, permeability and at least one molecular descriptor associated with the compound of interest.Type: ApplicationFiled: June 5, 2003Publication date: September 16, 2004Inventors: George M. Grass, Glen D. Leesman, Daniel A. Norris, Patrick J. Sinko, Jehangir Athwal, Carleton Sage, Troy Bremer, Kevin Holme, Yong-Hee Lee, Kyoung Lee
-
Publication number: 20040039530Abstract: A system for simulating metabolism of a compound in a mammal is disclosed that includes a metabolism simulation model of a mammalian liver. This model has equations which, when executed on a computer, calculate the rate of metabolism of the compound in the cells of the mammalian liver and a rate of transport of the compound into the cells, wherein the simulation model determines an amount of the metabolism product. The rate of metabolism may be a rate of depletion of the compound. The metabolism product may be an amount of the compound remaining after the compound's first passage through the mammalian liver (This is not necessarily limited to first pass, nor would it need to be limited to the liver. Intestinal metabolism could also be modeled). The rate of metabolism may alternatively be a rate of accumulation of a metabolite of the compound.Type: ApplicationFiled: May 30, 2003Publication date: February 26, 2004Inventors: Glen D Leesman, Daniel A Norris, Patrick J Sinko, Kevin Holme, Tatyana Izhikevich, Julie Doerr-Stevens, Edward Lecluyse, Dhiren R Thakker, George M Grass
-
Publication number: 20040009536Abstract: A method for developing a predictive model of a chemical compound property. The method includes obtaining at least one descriptor from structural data for each of a plurality of compounds. At least one chemical compound property is obtained for each of the plurality of compounds. The predictive model is developed by mapping the at least one descriptor to the chemical compound property. The chemical compound property may be an ADME property. The ADME property may be absorption. The chemical compound property may also be an toxicity property.Type: ApplicationFiled: May 30, 2003Publication date: January 15, 2004Inventors: George Grass, Glen D Leesman, Daniel Norris, Patrick Sinko, Jehangir Athwal, Carleton Sage, Troy Bremer, Kevin Holme
-
Publication number: 20030215497Abstract: An adjuvant composition which is a stable oil-in-water emulsion comprising a metabolizable oil, one or more surfactants, an antioxidant and a compound to make the emulsion isotonic is described and claimed. The stable emulsion has a hydrophobic-lipophilic balance (HLB) of from about 7.5 to about 10.5 and a particle size of less than 3 &mgr;m.Type: ApplicationFiled: June 10, 2003Publication date: November 20, 2003Applicant: Ribi Immunochem Research, Inc.Inventor: Glen D. Leesman
-
Patent number: 6647358Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: GrantFiled: May 26, 1999Date of Patent: November 11, 2003Assignee: Lion Bioscience AGInventors: George M. Grass, Glen D. Leesman, Daniel A. Norris, Patrick J. Sinko, John E. Wehrli
-
Patent number: 6630161Abstract: An adjuvant composition which is a stable oil-in-water emulsion comprising a metabolizable oil, one or more surfactants, an antioxidant and a compound to make the emulsion isotonic is described and claimed. The stable emulsion has a hydrophobic-lipophilic balance (HLB) of from about 7.5 to about 10.5 and a particle size of less than 3 &mgr;m. In a preferred embodiment, the stable emulsion comprises 10% volume to volume squalene, 0.09% weight to volume PLURONIC F-68 block co-polymer, 1.9% weight to volume egg phosphatidyl choline, 1.75% volume to volume glycerol and 0.05% weight to volume &agr; tocopherol. The preferred emulsion has a HLB of 8.0 and a particle size of about 0.2 &mgr;m. In a particularly preferred embodiment, the stable emulsion is combined with an attenuated lipid A derivative such as monophosphoryl lipid A or 3-deacylated monophosphoryl lipid A to enhance the adjuvanticity of the composition.Type: GrantFiled: May 7, 1999Date of Patent: October 7, 2003Assignee: Ribi Immunochem Research, Inc.Inventor: Glen D. Leesman
-
Patent number: 6542858Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver: The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: GrantFiled: May 26, 1999Date of Patent: April 1, 2003Assignee: Lion Bioscience AGInventors: George M. Grass, Glen D. Leesman, Daniel A. Norris, Patrick J. Sinko, John E. Wehrli
-
Publication number: 20020061540Abstract: A secondary compound library produced by a method of screening a compound library or portion thereof by absorption is provided. The method includes a step (i) that screens a primary compound library or portion thereof having a plurality of test samples containing isolated compounds or isolated mixtures of compounds per test sample by generating an in vivo absorption profile for each of the test samples from initial dose data and from in vitro bioavailability data comprising permeability and solubility data for each of the test samples, wherein the absorption profile includes at least one of rate of absorption, extent of absorption, and concentration of a test sample. Step (ii) produces a secondary compound library that includes at least one compound from the primary compound library having a desired absorption profile.Type: ApplicationFiled: November 21, 2001Publication date: May 23, 2002Applicant: Lion Bioscience AGInventors: George M. Grass, Glen D. Leesman, Daniel A. Norris, Patrick J. Sinko, John E. Wehrli
-
Publication number: 20020035459Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: ApplicationFiled: May 26, 1999Publication date: March 21, 2002Inventors: GEORGE M. GRASS, GLEN D. LEESMAN, DANIEL A. NORRIS, PATRICK J. SINKO, JOHN E. WEHRLI
-
Publication number: 20020013662Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: ApplicationFiled: May 26, 1999Publication date: January 31, 2002Inventors: GEORGE M. GRASS, GLEN D. LEESMAN, DANIEL A. NORRIS, PATRICK J. SINKO, JOHN E. WEHRLI
-
Publication number: 20020010550Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: ApplicationFiled: May 26, 1999Publication date: January 24, 2002Inventors: GEORGE M. GRASS, GLEN D. LEESMAN, DANIEL A. NORRIS, PATRICK J. SINKO, JOHN E. WEHRLI
-
Publication number: 20010041964Abstract: The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver. The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data.Type: ApplicationFiled: May 26, 1999Publication date: November 15, 2001Inventors: GEORGE M. GRASS, GLEN D. LEESMAN, DANIEL A. NORRIS, PATRICK J. SINKO, JOHN E. WEHRLI
-
Patent number: 6153592Abstract: Proteins or peptidic substances, which may be prepared from naturally occurring proteins, enhance the bioavailability of proteolytically-labile therapeutic agents which, in the absence of the protein or peptidic substance would suffer enzymatic inactivation upon administration.Type: GrantFiled: September 8, 1994Date of Patent: November 28, 2000Assignee: Port Systems, LLCInventors: Gordon L. Amidon, Glen D. Leesman, Patrick J. Sinko
-
Patent number: 5387421Abstract: A drug delivery system includes a first capsule half having an inner chamber for containing a drug therein. A plug is disposed in a passageway of the capsule half for plugging the opening thereof. The plug is releasable from the passageway opening upon the application of pressure from within the inner chamber. A pump mechanism causes an increase in pressure within the inner chamber and forces the plug out of the passageway to release the drug from the inner chamber and out of the passageway thereby providing a second pulse of drug release at a predetermined time after initial ingestion of the capsule. The invention further provides a method of manufacturing the drug delivery system and method by which the drug delivery system provides the drug to the body.Type: GrantFiled: May 31, 1994Date of Patent: February 7, 1995Assignee: TSRL, Inc.Inventors: Gordon L. Amidon, Glen D. Leesman, Lizbeth B. Sherman
-
Patent number: 5229131Abstract: A drug delivery system for administering a drug in controlled pulse doses to an aqueous environment in the body of a living being has one or more, and preferably less than ten, individual drug-containing subunits in a unitary drug depot, such as a tablet or capsule. The individual subunits are designed to dissolve at different sites and/or times in the gastrointestinal tract to release pulse doses of drug into the portal system in an analogous manner to the rate of release from an immediate release dosage form administered according to an appropriate dosing schedule. The dissolution time of the individual subunits can be controlled by several methods including the provision of pH-sensitive enteric coatings and permeability-controlled coatings. The drug delivery system has significant advantages for the oral administration of first-pass metabolized drugs which exhibit a non-linear relationship between input rate of the drug into the portal system and bioavailability.Type: GrantFiled: October 7, 1991Date of Patent: July 20, 1993Assignee: University of MichiganInventors: Gordon L. Amidon, Glen D. Leesman